Literature DB >> 17619127

Enhanced in vivo protein synthesis in circulating immune cells of ICU patients.

Anna Januszkiewicz1, Maria Klaude, Karin Loré, Jan Andersson, Olle Ringdén, Olav Rooyackers, Jan Wernerman.   

Abstract

Insufficient function of the immune system contributes to a poor prognosis in intensive care unit (ICU) patients. However, the immune system function is not easily monitored and evaluated. In vivo protein synthesis determination in immune competent cells offers a possibility to quantify immunological activation. The aim of this descriptive study was to determine the in vivo fractional protein synthesis rate (FSR) in immune cells of ICU patients during the initial phase of the critical illness. Patients (n = 20) on ventilator treatment in the general ICU were studied during their first week of ICU stay. FSR was determined in circulating T lymphocytes, mononuclear cells, the whole population of blood leukocytes, and in stationary immune cells of palatine tonsils during a 90-min period by a flooding technique. Healthy, adult subjects (n = 11), scheduled for elective ear, nose, and throat surgery served as a control group. The FSR in leukocytes and mononuclear cells of ICU patients was higher compared with the control group. In contrast, the FSR of circulating T lymphocytes and of tonsillar cells was not different from that in the healthy subjects. In summary, the ICU patients showed a distinct polarization of metabolic responses during the initial phase of the critical illness. The in vivo rate of protein synthesis was high in the circulating mononuclear cells and leukocytes, reflecting enhanced metabolic activity in these cell populations. Determination of the in vivo protein synthesis rate may be used as a tool to obtain additional information on activation of the immune system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17619127     DOI: 10.1007/s10875-007-9108-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  25 in total

1.  The immunologic response to injury.

Authors:  J A Mannick; M L Rodrick; J A Lederer
Journal:  J Am Coll Surg       Date:  2001-09       Impact factor: 6.113

2.  Response of in vivo protein synthesis in T lymphocytes and leucocytes to an endotoxin challenge in healthy volunteers.

Authors:  A Januszkiewicz; K Loré; P Essén; B Andersson; M A McNurlan; P J Garlick; O Ringdén; J Andersson; J Wernerman
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

3.  Sir Isaac Newton, sepsis, SIRS, and CARS.

Authors:  R C Bone
Journal:  Crit Care Med       Date:  1996-07       Impact factor: 7.598

Review 4.  Immunomodulatory therapies in sepsis.

Authors:  W J Kox; T Volk; S N Kox; H D Volk
Journal:  Intensive Care Med       Date:  2000       Impact factor: 17.440

Review 5.  Sepsis syndromes: understanding the role of innate and acquired immunity.

Authors:  A Oberholzer; C Oberholzer; L L Moldawer
Journal:  Shock       Date:  2001-08       Impact factor: 3.454

6.  HLA-DR expression and soluble HLA-DR levels in septic patients after trauma.

Authors:  M Ditschkowski; E Kreuzfelder; V Rebmann; S Ferencik; M Majetschak; E N Schmid; U Obertacke; H Hirche; U F Schade; H Grosse-Wilde
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

7.  Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis.

Authors:  P Loisa; T Rinne; S Laine; M Hurme; S Kaukinen
Journal:  Acta Anaesthesiol Scand       Date:  2003-03       Impact factor: 2.105

8.  Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression.

Authors:  R Y Lin; M E Astiz; J C Saxon; E C Rackow
Journal:  Chest       Date:  1993-09       Impact factor: 9.410

9.  Alteration of monocyte function following major injury.

Authors:  E Faist; A Mewes; T Strasser; A Walz; S Alkan; C Baker; W Ertel; G Heberer
Journal:  Arch Surg       Date:  1988-03

Review 10.  Clinical review: immunodepression in the surgical patient and increased susceptibility to infection.

Authors:  Martin K Angele; Eugen Faist
Journal:  Crit Care       Date:  2002-05-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.